spacer
home > ict > winter 2018 > promoting patterns
PUBLICATIONS
International Clinical Trials

Promoting Patterns

The clinical trial industry is transforming, and the vision for this is simple: embrace quality and automation across the clinical trial spectrum and move closer to zero-delay trials. Why? It provides better, faster results, offers more information for sponsors, allows more innovation for CROs, and, most importantly, presents expedited outcomes for patients in need. This transformation is just beginning and requires that we challenge ourselves, our teams, partners, and clients – the entire clinical trial industry – to work smarter and eliminate preventable delays.

Data Dilemmas

Drug or device trials are fundamentally science experiments. Everyone has some familiarity with how that works from those exciting high school or college labs where one measured some Newtonian physics principle. However, unlike those, in clinical trials, the outcome is unknown, and the data are never as crisp and predictable. For the most part, the signalto- noise ratio is exceedingly small. If the data collection or the analysis processes adds more noise to the system, the signal may become undetectable. When that happens, therapies that might have helped patients in need may never be approved because the data was not handled appropriately.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Abraham Gutman founded AG Mednet in 2005 and leads the company’s mission to improve, automate, and expedite outcomes in clinical trials by ensuring quality and compliance within drug, biologic, and device trials. Abraham holds a BA in computer science from Cornell University and an MSc in computer science from Yale University, US.
spacer
Abraham Gutman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Source BioScience invest in digital pathology platform to enhance the outsourced histopathology service solution provided to the NHS and private healthcare

As a leading provider of outsourced histopathology services to the NHS and private healthcare centres in the UK Source BioScience has, after a detailed review of all other available alternatives in the digital marketplace, unveiled investment in a digital pathology platform from their preferred partner, Philips.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

4th Annual Formulation & Drug Delivery Congress

8-9 May 2018, London, UK

Oxford Global are proud to present our hugely popular 4th Annual Formulation & Drug Delivery Congress, 8th – 9th May 2018, London, UK.Over 300 delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will gather for over 40 presentations and case studies focused on the key issues in large molecule and small molecule drug formulation and drug delivery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement